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1. INTRODUCTION 
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1.1 Glaucoma 
The term „glaucoma“ originates from the ancient Greek word glaukos, meaning 
“bright, glowing, shiny” specifically for the sea: grey-bluish and comes from the blue-grey 
discoloration of the iris after chronic inflammation (1). 
In the routine practice of ophthalmology, the term glaucoma is applied to all patients 
having an increased intraocular pressure (IOP) with or without glaucomatous damage, as well 
as to patients suffering from glaucomatous damage (with or without high IOP).  
 An elevated intraocular pressure is an important risk factor for glaucoma. Many 
people have an average IOP of 10-21 mmHg with a mean value of 15 mmHg. The most 
common cause for an increase in IOP is a decreased outflow of aqueous humour through the 
iridocorneal angle and high resistance in the trabecular meshwork. Nevertheless almost 40% 
of glaucoma patients have normal intraocular pressure (Normal tension glaucoma), but are 
very sensitive to blood pressure fluctuations (2,3). 
In glaucoma, retinal nerve cells and retinal nerve fibres progressively die, leading to 
cupping or excavation of the nerve head. Consequentially, the connection between the eye and 
brain, which is crucial for vision, is gradually destroyed. Light can be seen but transmission of 
visual information to the brain is interrupted. As a result, defects in the visual field develop 
which, in the beginning, go unnoticed by the patient. Early detection of glaucoma is crucial 
(3). 
The International Glaucoma Association (IGA) estimates that about 2% of people in 
the UK over the age of 40 are affected by Glaucoma (4). The global prevalence of glaucoma 
for population aged 40–80 years is 3.54%. Especially Africa and Asia show higher numbers 
in incidence of Glaucoma. In 2013, the number of people (aged 40–80 years) with glaucoma 
worldwide was estimated to be 64.3 million, increasing to 76.0 million in 2020 and 111.8 
million in 2040 (5). 
In the Croatian town Split, the regional capital of the Split-Dalmatian County, the 
mean incidence of acute closed angle glaucoma in the years between 1985 -1999 was 4.1 on 
100.000 inhabitants in the whole population (6). 
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1.2 Classification of different types of Glaucoma 
1.2.1 Congenital Glaucoma 
Primary congenital glaucoma is rare but has an important impact on child's 
development and quality of life. Early detection and appropriate therapy make a major 
difference in the visual outcome and can prevent lifelong disability. Surgical treatment is 
unavoidable. According to the age of appearance it is divided into (13,14):  
I.  Primary congenital glaucoma (PCG): from birth to >2 years of life 
II. Late-onset childhood open angle glaucoma or Infantile glaucoma:  onset >2 to  
puberty 
III. Juvenile glaucoma: from puberty to 35 years 
In secondary congenital glaucoma many pathogenic mechanisms are possible. Medical 
treatment usually is non-effective nor is it doable in long term. Medications which include 
oral Carbonic Anhydrase Inhibitors (CAIs) can be used in the time while decision is made 
about the surgical approach and in case of failed surgery while awaiting for further options 
(15).                                                                                  
The treatment of primary congenital glaucoma cases is particularly challenging 
because of the nature of the disease and the difficulties in operating them and examining 
patients in this age group. Treatment has to be adapted to the leading anomaly and the 
mechanism of IOP elevation. If possible concerned patients should be referred to tertiary care 
centres (15). 
1.2.2 Primary open-angle glaucoma (POAG) 
Open-angle glaucomas are chronic progressive optic neuropathies (ON) that are 
defined by characteristic morphological changes at the optic nerve head (ONH) and retinal 
nerve fibre (RNFL) without other ocular disease or congenital anomalies. Progressive retinal 
ganglion cells (RGC) death and visual field loss (VFL) are associated with these changes. 
Glaucoma is the second leading cause of blindness both in Europe and worldwide. It is the 
most frequent cause of irreversible blindness. POAG is treated by reducing intraocular 
pressure using medication, laser, surgery or sometimes in combination (16). 
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Consideration of risk factors helps to identify patients for early detection and to guide 
management decisions about the initiation and increase of treatment in established glaucoma 
patients. 
Risk factors are: Age, intraocular pressure (IOP), race, family history, 
pseudoexfoliation (PEX), central corneal thickness (CCT), myopia, ocular perfusion pressure, 
diabetes m., systemic blood pressure (BP), migraine, Raynaud Syndrome and obstructive 
sleep apnoea.  
Factors that are linked with the advance of established POAG have been identified by 
large RCT. The factors are: Age, IOP, pseudoexfoliation, CCT, disc haemorrhages (15). 
POAGs divide into several types: 
I. High pressure glaucoma (POAG/HPG) 
The risk for POAG advances continuously with the level of IOP without evidence of a 
threshold IOP for the onset of the condition. The aetiology is not known. It can start in early 
adulthood. Typical Symptoms of HPG are that the condition is asymptomatic until field loss 
advances, elevated IOP without treatment, characteristic glaucomatous damage at the optic 
nerve head and detectable glaucomatous defects in the visual field and in optical coherence 
tomography (OCT) in correspondence to the optic disc damage. Treatment forms are: drugs 
including monotherapy or combination therapy in selected patients, different types of 
filtration surgery like penetrating and non-penetrating procedures or laser trabeculoplasty 
(ALT or SLT) with adjunctive medical therapy when needed (15). 
II. Normal pressure glaucoma (POAG/NPG) 
Aetiology is not known. It can occur from the age 35 onwards. It stays asymptomatic 
until field loss advances. Symptoms are optic nerve head damage typical of glaucoma and 
disc haemorrhages. Treatment options are medical therapy: any effective and tolerated drug 
alone or in combination whose IOP lowering effect is efficient to reach or maintain the target 
IOP. Vasoconstrictive drugs or medications with systemic hypertensive effects should not be 
used. Laser trabeculoplasty is also a treatment option (15).  
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III. Infantile forms of glaucoma 
It can occur beyond infancy, usually after puberty or early adulthood and can be 
hereditary. There is no enlargement of the globe and it is asymptomatic until field loss is 
advanced. IOP is elevated without treatment. There is diffuse optical nerve head damage with 
glaucomatous defects which are present in visual field. No congenital or developmental 
anomalies are present. Therapy is any effective and well tolerated topical regimen. Laser 
trabeculoplasty is not recommended due to poor and short lived IOP lowering effect (15). 
IV. Ocular hypertension (OH) 
The aetiology is unknown. Signs and Symptoms include IOP above 21 mmHg without 
treatment. The visual field is normal. Optic disc and retinal nerve fibre layer are normal. No 
history or signs of other eye disease or steroid use should be present. Other risk factors are not 
known. A modest increase in IOP is not a sufficient reason for treatment but should be 
considered in patients with repeated IOP in the high 20s. If left untreated up to 9.5% develop 
glaucoma over a 5 year follow up. Each patient should be assessed individually (15). 
1.2.3 Primary closed angle glaucoma (PCAG) 
Angle closure is defined by presence of irido-trabecular contact (ITC). This can be 
either appositional or synechial. Gonioscopy is the standard technique for diagnosing ITC. 
Primary Angle closure result from crowding of the anterior segment and usually occurs in 
eyes with smaller than average anterior segment dimensions. PAC damages ocular tissue in 
many ways. High IOP values cause the iris to suffer ischemic damage. Angle closure leads to 
50% of all glaucoma blindness in the world and also the most visually destructive form of 
glaucoma. PAC is more common among Asian people than those from Europe as population 
surveys shown (43). Primary glaucoma cases have to be examined and an open anterior 
chamber angle should be shown on gonioscopy before PACG is excluded (17). 
Provocative tests for angle-closure are of little use since even when they are negative, 
a potential for angle-closure persists. In addition those tests can be dangerous by leading to an 
acute angle-closure attack even while the patient is monitored. 
The mechanisms responsible for angle closure are described in terms of anatomical 
location of obstruction to aqueous flow:  at the pupil, the iris, the ciliary body, the lens and 
behind the lens.  
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1. Acute angle closure (AAC) with pupillary block mechanism 
It is defined by circumferential iris apposition to the trabecular meshwork with fast 
and excessive rise in IOP that does not resolve spontaneously. Symptoms are: IOP > 21 
mmHg often 50-80 mmHg, decreased visual acuity, corneal edema, blurred vision with pain 
and “halos”. Iridectomy or Iridotomy together with medical treatment is performed (15). 
 
2. Acute Angle-Closure (AAC) with plateau iris configuration 
In plateau iris configuration the iris plane is flat and narrowing the anterior chamber 
angle due to insertion of the iris anteriorly on the ciliary body. This alters the position of the 
peripheral iris in relation to trabecular meshwork (18). 
 
3. Intermittent Angle-Closure (IAC) 
Here signs may vary according to the amount of iridotrabecular contact of chamber 
angle and mimic acute angle-closure in mild form. 
 
4. Chronic angle closure glaucoma (CACG) 
CACG is defined by permanent synechial closure of any extent of the chamber angle 
as confirmed by gonioscopy. Signs include peripheral anterior synechiae of any degree at 
gonioscopy. The IOP is above 21 mmHg. There is usually no pain, visual disturbances occur 
according to functional states (15). 
 
1.2.4 Secondary Open Angle Glaucoma (SOAG) 
Secondary glaucomas are a heterogeneous group of conditions in which elevated IOP 
is the leading pathological factor causing glaucomatous optic neuropathy. SOAG can be 
caused by ocular disease or iatrogenic: (15) 
I. Secondary Open-Angle glaucoma caused by ocular disease 
a. Exfoliative (pseudoexfoliative) glaucoma 
i. XFG is the most common type o secondary open-angle glaucomas. It 
usually occurs in persons older than 60 years. It is asymptomatic until 
visual field loss is advanced. One or both eyes are affected usually 
asymmetrical. IOP is above 21 mmHg, frequently higher than in 
average POAG cases (19). 
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b. Pigmentary Glaucoma (PG) 
i. Melanin granules cause an increase of trabecular meshwork outflow 
resistance and lead to an elevation of IOP. It represents 1-1.5% of all 
glaucoma cases. Patients may experience transient visual blurring or 
halos during episodes of IOP rise. It can be either unilateral or bilateral 
(20). 
c. Lens induced open-angle Glaucoma  
i. The trabecular meshwork outflow pathways are obstructed by lens 
particles and/or inflammatory cells. Patients usually suffer from 
unilateral pain with redness and inflammation. Vision is reduced and 
IOP is elevated (21). 
d. Glaucoma associated with intraocular haemorrhage 
i. Either acute bleeding in the anterior chamber or long standing blood in 
the vitreous of any source can cause IOP elevation. Symptoms are pain 
and eye irritation. Elevated IOP is more often due to recurrent 
haemorrhage or re-bleeding (15). 
e. Glaucoma due to intraocular tumour  
i. It represents with reduced aqueous humor outflow due to primary or 
secondary intraocular tumours mainly of the anterior segment. 
Symptoms and signs are elevated IOP. A highly variable clinical 
picture, combining evidence of both tumour and glaucoma (22). 
f. Open angle glaucoma due to ocular trauma  
i. This condition can be caused by blunt non-penetrating or penetrating 
trauma to the eye.  Trauma can lead to reduced trabecular outflow due 
to traumatic changes to the trabecular meshwork. Penetrating injury 
may damage one or more intraocular structures leading to elevated IOP 
(15). 
II. Iatrogenic secondary open-angle glaucomas 
a. Glaucoma due to corticosteroid treatment 
Topical, intravitreal as well as high dose and long term systemic 
corticosteroid therapy may induce acute or chronic IOP elevation. 
Corticosteroids lead to changes in the trabecular extracellular matrix 
which can cause decreased outflow (23, 24). 
8  
b. Secondary open-angle glaucoma due to ocular surgery and laser therapy 
i. Ocular surgery can cause secondary open-angle glaucoma by 
intraocular haemorrhage, inflammatory reaction, lens material, 
pigmentay loss from uveal tissue, or trauma (25). 
1.2.5 Secondary closed-angle glaucoma (SCAG) 
There are many different causes of secondary closed-angle glaucoma and the clinical 
signs vary according to the underlying condition 
I.  Secondary closed-angle glaucoma with pupillary block 
Pupillary block pushes the iris forward to occlude the angle. It can be caused by 
enlarged swollen lenses, anterior lens dislocation (Trauma, zonular lexity, Marfan Syndrome, 
etc.) 
II. Secondary closed-angle glaucoma without pupillary block 
The trabecular meshwork is obstructed by iris tissue or a membrane. The iris and/or a 
membrane are progressively pulled forward to occlude the angle. IOP is >21mmHg (15). 
1.3 Risk factors for development of glaucoma 
1. Age 
The prevalence of glaucoma increases dramatically with age. Two studies reported a 
6% and 4% increased risk per year of age as baseline of developing glaucoma (15). 
2. Intraocular pressure 
Higher IOP has been consistently associated with the prevalence and incidence of 
glaucoma. The risk of developing glaucoma increases by 11-12% in Caucasians, 10% 
in people of African origin and 18% in Latinos for each 1 mmHg in IOP (26-27). 
3. Race/Ethnicity 
The prevalence of glaucoma is several times higher in African Americans and Afro 
Caribbeans than in Caucasians (28-29). 
4. Positive Family History of Glaucoma 
Studies have shown that the risk factor of having glaucoma 4-9 times higher for 
individuals having first degree relative with glaucoma compared to those who do not 
have glaucoma (30-31). 
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5. Pseudoexfoliation (PEX) 
Population based studies reported that pseudoexfoliation is associated with 11 fold 
increased risk of development of glaucoma (26). 
6. Central corneal Thickness (CCT) 
7. Myopia 
A Dutch study showed that subjects with high myopia (>4D) had a 2.3-fold increased 
risk for developing glaucoma (27). 
8. Ocular perfusion pressure  
Population based studies have shown that low ocular perfusion pressure is associated 
with increased glaucoma prevalence (28,32). 
9. Other factors 
Systemic and/or systemic vascular risk factors like Diabetes mellitus, systemic blood 
pressure, ocular perfusion pressure, migraine, Raynaud syndrome and obstructive 
sleep apnoea (15). 
1.4 Diagnosis of glaucoma 
Early diagnosis of glaucoma is of great importance because treatment is likelier to 
succeed when begun early than when damage to the nerve has already progressed to an 
advanced stage. Detecting glaucoma is only possible if the patient visits the ophthalmologist 
and early state changes of glaucomatous damage are sometimes hardly differentiated from 
variations that are harmless. There is often a period of uncertainty as to whether or not the 
patient will develop glaucomatous damage (3).  
1.4.1 Routine eye examination 
 The ophthalmologist will first check visual acuity (VA), a measure of the optical 
resolution or the eyes discernment, i.e. how well one can read and recognize things, people, 
traffic signs, etc. from a distance and up-close. If the visual acuity is identical to the general 
healthy population, it is 1.0, 100%, or 20/20. A patient with visual acuity of 0.5 (50%) or 
20/40 needs the chart letters 20 to size of someone having 20/20 vision. In glaucoma, visual 
acuity stays normal for quite some time. However many glaucoma patients suffer form a 
reduced visual acuity because they also have other eye diseases, such as cataract (3). 
1.4.2 Measuring the intraocular pressure  
Tonometry is another term for measuring the IOP. The international standard in 
ophthalmology is The Goldmann applanation tonometer (GAT). Applanation tonometry 
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measures the force that is necessary to flatten (i.e. to applanate) a defined part of the cornea. 
The instruments are calibrated so that the IOP can be read from a graduated dial. 
Non-contact devices flatten the cornea using a jet of air. An optic receiver detects 
when and how fast the cornea has been flattened to a predetermined degree. This method’s 
advantage lies in the face that local anaesthetic is not required and potential contamination 
from a tonometry cylinder is prevented. However, the measurement is not as accurate as 
Goldmann’s tonometry, particularly with high IOP levels (3).  
1.4.3 Examining the anterior chamber angle (gonioscopy) 
The examination of the chamber angle is called gonioscopy. The method is used when 
investigating the cause for an IOP increase or when there is some indication that the angle 
could close, thereby triggering an acute glaucoma attack. The physician uses a special contact 
glass, a gonio lens, to perform gonioscopy. After applying a local anaesthetic, the gonio lens 
is placed upon the eye. Using this technique, the angle can be checked for material that should 
not be there. (blood, cell-debris or signs of inflammation) (3) 
1.4.4 Evaluating the optic disc (ONH) 
Evaluating the optic disc is the most important step in diagnosing glaucoma. The size 
of the optic nerve head (ONH) is assessed first as well as the cup-disc ratio (CDR). Atrophy 
around the papilla can indicate glaucomatous damage, but it can also occur in other diseases 
and even in healthy eyes. However a small haemorrhage at the rim of the optic disc is almost 
always sign of glaucoma, especially when other eye diseases have been ruled out. Disc 
haemorrhages are markers of progressing glaucomatous damage. Local vasoconstriction of 
retinal vessels is a local sign of glaucoma (3). 
1.4.5 Slit lamp exam 
The slit lamp is a special ophthalmological microscope that swivels so that the eye and 
its interior parts can be viewed from various angles. It is equipped with a light source that is 
also moveable. The light beam usually takes the form of a slit, thereby enabling the eye to be 
examined in different layers, i.e. “optical sections” (3). 
1.4.6 Measuring central corneal thickness (CCT/ pahimetry) 
Corneal thickness can be measured with optical devices, nowadays with ultrasound 
and laser pahimeters. At the given real IOP, the thicker the cornea, the higher are the 
measured IOP values, and vice versa. The IOP Diagnosis can be overestimated or 
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underestimated (ocular hypertensives, persons with thin corneas). It must be noted that an IOP 
at which glaucomatous damage occurs or progresses is always too high. It is to date not clear 
whether thin cornea is a risk factor for glaucomatous damage independent of IOP level but we 
know it is associated with myopia (3).  
1.4.7 Testing the Visual Field (vF) 
Evaluation of the visual field is called perimetry. It plays a critical role in diagnosing 
glaucoma and in monitoring the diseases progression. Only perimetry can provide conclusion 
about patient’s visual function and is of primary importance in analysing the progression of 
changes in visual field. In glaucoma, typical visual field defects appear. Characteristic nerve 
fibre bundle defects are caused by the demise of one or several adjusting nerve fibre bundles. 
There are a lot of other non specific defects in glaucoma that generally make it difficult to 
assess whether a visual field defect is due to glaucoma or to some other disease. In glaucoma, 
the type of the defect is less important than the total amount of tissue and functional loss. 
1.4.8 Optic coherence tomography (OCT) 
The loss of nerve fibers that lead from the retinal surface to the optic disc is one 
component of glaucomatous atrophy. OCT is a diagnostic instrument for measuring the nerve 
fiber layer thickness. It employs the basic imaging principle similar to the ultrasound B-scan. 
(3). 
1.5 Therapy of glaucoma 
The goal of glaucoma treatment is to maintain the patient’s visual function and related 
quality of life (QoL), at sustainable costs. The cost of treatment in terms of inconvenience and 
side effects as well as financial implications for the individual and society requires careful 
evaluation. Quality of life is closely linked with visual function and, overall, patients with 
early to moderate glaucoma damage have good visual function and modest reduction in 
quality of life (QoL), while quality of life is considerably reduced if both eyes have advanced 
visual function loss. Individualized glaucoma treatment aims at providing glaucoma 
management tailored to the individual needs of the patient (3). Patients with severe functional 
loss or younger patients with manifest disease should have more aggressive treatment and 
closure follow up than patients with little or no risk, e.g., patients with ocular hypertension or 
elderly patients with mild field loss and low IOP levels. Intraocular pressure can be reduced 
by:  different medications, laser treatments or Surgery (3). 
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1.5.1  Original antiglaucoma drugs  
1.5.1.1 Parasympatomimtic agents/ cholinergic agents 
The neurotransmitter released by the nerve cell endings is called acetylcholine. Drugs 
that mimic the effect of acetycholine are called cholinergic agents or parasympatomimetics. 
Pilocarpine: 
Pilocarpine is the most important drug from among the cholinergic agents. It is a so 
called alkaloid that is a basic component produced by plants. It is available as eye drops and 
ointment, administered in concentration ranging from 0.5% to 3%, and easily penetrates into 
the eye. About half an hour after application the IOP starts to drop, and the lowering effect 
lasts between 4-8 hours. It must be administered at least 3-4 times a day (3,37).  
1.5.1.2 Sympathomimetic Agents (Alpha-2 selective agonist) 
Substances that mimic or enhance the effects of the sympathetic nervous system are 
called sympathomimetic agents. Alpha 1 receptors are located post-synaptically and have a 
sympathomimetic effect while alpha 2 receptors are located pre- and post-synaptically 
ultimately exhibiting an sympatholytic effect. In glaucoma therapy, alpha-2 selective 
medications are generally used, including drugs such as clonidine, apraclonidine and 
brimonidine (3). 
I. Brimonidine (Alphagan, Allergan Pharmaceuticals Ireland, Westport, Ireland)  
 
Alphagan is available in form of eye drops, 2 mg/ml. The drug is administered in 
concentration of 0,2%. The mechanism of action is diminished production of aqueous humor 
and eases uveoscleral flow (3,37). 
1.5.1.3  Sympatholytic Agents (β-Blockers) 
Sympatholytic Agents inhibit the sympathic part of the nervous system. Beta receptors 
in the ciliary body are responsible for the production of aqueous humour and their blockage 
leads to decreased production of  aqueous humour and lowering of eye pressure. They 
provoke following side-effects: allergies, dry eyes, worsening of accommodation, reactivation 
of lung disease such as asthma, AV block, hypotension, weakness and depression (3). 
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I. Timolol: (Timalen, Jadran Galenski laboratorij d.d., Rijeka, Croatia) 
Timalen is a non-selective beta-blocker. It is available as eye drops, 2mg/ml and 
5mg/ml. The medication is applied two times daily in a concentration of 0.25% to 0.5%. 
Blocking beta receptors leads to decreased production of aqueous humor and lowering of IOP. 
It has the most significant effect in lowering IOP amongst all beta blockers. Its main side 
effect is bronchospasm in prone patients (3,37).  
II. Betaxolol: (Betoptic, Alcon Cusi S.A., EI Masnou, Barcelona, Spain; Alcon 
Couvreur N.V., Puurs, Belgium) 
Betoptic is a selective beta-blocker available as eye drops, 5 mg/ml. It is applied two 
times daily in a concentration of 0.5%. Betoptic has better effect compared to Timalen. It 
predominantly blocks beta-1 receptors and causes less problems with asthmatic patients than 
Timalen. It can speed up microcirculation and is neuroprotective (3,37).  
III. Levobunolol:  (Vistagan, Allergan Pharmaceuticals Ireland Ltd., Westport, 
Ireland)  
Vistagan is available as eye drops, 5 mg/ml. The drug is applied two times in a 
concentration of 0.5%. By blocking beta receptors which are responsible for the production of 
aqueous humour in the ciliary body it leads to reduction of production of aqueous humour and 
a reduction of IOP (3,37). 
1.5.1.4  Carbonic Anhydrase Inhibitors (CAI) 
Carbonic Anhydrase is an enzyme that catalyzes the transformation of carbon dioxide 
and water into bicarbonate and vice versa. The enzymes activity can be blocked by carbonic 
anhydrase inhibitors (CAI). CAI lead to vasodilation in ocular as well as cerebelar blood 
vessels. This vasodilatative effect may be quite advantagous in the treatment of glaucoma (3). 
I. Dorzolamid: (Trusopt, Merck Sharp & Dohme – Chibret, Clermont – Ferrand, 
France) 
Trusopt is available as eyedrops, 20 mg/ml. The drug exerts its effect in inhibiting 
carbonic anhydrase, which results in lowered lower production of aqueous humour. It is 
applied 2-3 x per day (3,37). 
II. Brinzolamid (Azopt, S.A. Alcon Couvreur N.V., Puurs, Belgium) 
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Azopt is available as eyedrops, 10mg/ml. The drug is applied two times daily in 1% 
local concentration. The drug inhibits carbonic anhydrase what results in lowered production 
of aqueous humour. Azopt has the same effect in lowering IOP like Oftidor and Trusopt but is 
available as suspension and not solution (3,37). 
1.5.1.5  Analogues of prostaglandines and prostamides 
Analogues of prostaglandin were only recently introduced into ophthalmology as 
opposed to inhibiting drugs that are being used since a long time in modern ophthalmology. 
The mechanism of these drugs works by increasing uveoscleral outflow of aqueous humour. It 
is the first line of antiglaucomatous treatment (AGT) (3).  
I. Latanoprost: (Xalatan, Pfizer Manufacturing Belgium NV, Puurs, Belgium) 
Xalatan is available in form of eye drops in 50mg/ml. The medication reduces IOP by 
accelerating outflow of aqueous humour and is the only anti-glaucoma medication that has an 
influence on the uveoscleral angle. It increases the uveoscleral angle for a prolonged period 
and needs application only once daily. The most important side effect of Xalatan is 
conjuctival hyperemia, so called „red eye“ leading to itching and a feeling of foreign body in 
the eye. It also can lead to irreversible pigmentation of the iris, prolongation of eyelashes and 
macular edema (3,37). 
II. Bimatropost, prostamid (Lumigan, Allergan Pharmaceuticals Ireland, Ireland) 
Lumigan is available in form of eye drops, 0.1 mg/ml, 0.3 mg/ml. The drug i applied 
once daily in the evening. Lumigan increases the flow of aqueous humour via the trabecular 
meshwork and uveoscleral angle. Side effect are moderate conjuctival hyperaemia (3,37) 
III. Travoprost: (Travatan, S.A. Alcon Couvreur N.V., Puurs, Belgium) 
Travatan is available as eye drops in 40 mg/ml. The medication is applied once daily 
in 0.004% concentration. The mechanism of action is the increase in uveoscleral outflow. Its 
side effects are similar to Xalatan (3,37). 
IV. Tafluprost: (Saflutan, Merck Sharp & Dohme B.V., Haarlem, Netherlands; 
Laboratoire Unither, Coutances, France) 
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Saflutan is available as eye drops in 15 mg/ml. Its mechanism of action is in the 
increase of uveoscleral outflow of aqueous humour (3,37). 
1.5.1.6 Fixed-dose combination drugs (FDC) 
Most therapies of glaucoma are limited to the use of mono-component drugs. A 
second drug from a different group is given if reduction of IOP with mono-component drugs 
is insufficient. Most commonly in use are combinations of two or three drugs from different 
groups with the maximum number of drops. Today pharmaceutical companies are preparing 
combinations in fixed form with two antiglaucoma drugs in one bottle (3). These are:  
I. Analogues of prostaglandin/prostamid + β-Blockers 
 Latanoprost + Timolol (Xalacom, Pfizer Manufacturing Belgium NV, Puurs, 
Belgium) 
 Travoprost + Timolol (Duotrav, S.A. Alcon Couvreur N.V., Puurs, Belgium) 
 Bimatropost + Timolol (Ganfort, Allergan Pharmaceuticals Ireland, Westport, 
Ireland) 
II. CAIs + β-Blockers 
 Dorzolamid + Timolol (Cosopt, Merck Sharp & Dohme B.V., Haarlem, 
Netherlands; Laboratories Merck Sharp & Dohme – Chibret, Clermont – 
Ferrand, France) 
 Brinzolamid + Timolol (Azarga, S.A. Alcon Couvreur N.V., Puurs, Belgium) 
III. Α-2 Agonists + β-Blockers 
Brimonidin + Timolol (Combigan, Allergan Pharmaceuticals Ireland, Westport) (3) 
 
Lately all Antiglaucoma Drugs are used without preservatives due to the susceptibility 
of the anterior eye segment to their toxic effects. Benzalkonium chloride (BAK) and Polyquad 
are the main conservans that are excluded because of their tendancy to cause ocular surface 
disease (OSD). 
1.5.2 Generic antiglaucoma medication 
 
A generic drug is supposed to be identical or bioequivalent to a brand name drug in 
dosage form, safety, strength, route of administration, quality, performance characteristics and 
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intended use. Despite their chemical identity to their branded counterparts, they are typically 
sold for lower price compared to the price of the original drug (7).  
As global spending on medicinal products continues to rise, the availability of lower-
cost generic substitutes is increasingly driving health care decision-making. Generic 
compounds may differ from innovator agents with regards to performance under 
environmental stress, relative acidity and bottle size/rigidity. Matching ingredient profiles 
may therefore not result in consistently comparable drug compositions and clinical effects (8). 
Ophthalmic generic compounds, however, must be identical in strength, dosage form, 
route of administration, have the same indications/contraindications, and abide by the same 
Good Manufacturing Practices standards as innovator agents (9). 
1.5.2.1 Sympathomimetic agents (Alpha-2 selective agonist) 
I. Brimonidine: (Luxfen, Pharma Stulln GmbH, Stulln, Germany; Sanitas AB, Kaunas,                                     
Lithuania)  
Luxfen is available in form of eye drops in 2mg/ml. The mechanism of action is 
diminished production of aqueous humor and eases uveoscleral flow.  It provokes reversible 
local side effects after 6 months of treatment, moderate decrease of blood pressure,tiredness 
and dry mouth. It can be combined with Timolol. 
II. Brimonidine: (Bimanox, Jadran Galenski laboratorij d.d., Rijeka, Croatia) 
Bimanox is available in form of eye drops in 2mg/ml. The drug decreses aqueous  
humor production and facilitates uveoscleral outflow. Side effects are similar to Luxfen. 
1.5.2.2 Sympatholytic agents (β-Blockers) 
I. Timolol: (Timlatan, S.C. Rompharm Company S.R.L., Otopeni, Romania) 
1.5.2.3 Carbonic anhydrase inhibitors 
           I. Dorzolamid:  (Oftidor, S.C. Rompharm Company S.R.L., Otopeni, Romania).  
 
Oftidor is available as eyedrops, 20 mg/ml. It is administered twice daily in a 2% 
solution. It leads to moderate IOP reduction. There are indications that dorzolamide exerts 
positive influence on ocular perfusion and is therefore of special benefit for patients who 
suffer from a disturbed bloodflow. Side effects may be slight burning sensation in the eye, 
bitter taste in the mouth and allergic reactions (3,37). 
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I. Dorzolamid: (Dorzol, Jadran Galenski laboratorij d.d., Rijeka, Croatia) 
 
Dorzol is available as eyedrops, 20 mg/ml. The drug exerts its effect in inhibiting 
carbonic anhydrase, which results in lowered lower production of aqueous humor. 
I. Dorzolamid (Ulom, Pliva Hrvatska d.o.o., Zagreb, Croatia) 
 
Ulom is available as eyedrops, 20 mg/ml. The drug exerts its effect in inhibiting 
carbonic anhydrase, which results in lowered production of aqueous humor (3,37). 
1.5.2.4 Analogues of prostaglandines and prostamid 
I. Latanoprost (Latanox, Jadran Galenski laboratoriji d.d., Rijeka, Croatia) 
 
Latanox is available as eye drops in 50 mg/ml. The mechanism of action of this 
drug is in the increase of uveoscleral outflow of aqueous humor. It has similar side 
effects to Xalatan.  
 
II. Latanoprost ( Latapres, S.C. Rompharm Company S.R.L., Otopeni, Romania) 
 
Latapres is available as eye drops in 50 mg/ml. Its mechanisms and side effects 
are similar to Latanox (3,37). 
1.5.2.5 Fixed-dose combination drugs (FDC) 
 
Carbonic anhydrase inhibitors + β-Blockers 
 Dorzolamid + Timolol (Oftidorix, Famar S.A., Athens, Greece) 
 Dorzolamid + Timolol (Glaumax, Jadran Galenski laboratorij d.d., Rijeka, 
Croatia) 
 Dorzolamid + Timolol (Ulom plus, Pliva Hrvatska d.o.o., Zagreb, Croatia) 
(3,37) 
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1.5.2.6 Systemic Antiglaucoma Drugs 
Hyperosmotic agents such as oral glycerine and intravenous mannitol can rapidly 
lower IOP by decreasing vitreous volume. They do not cross the blood-ocular barrier and 
therefore exert oncotic pressure that dehydrates the vitreous. Side effects associated with the 
hyperosmotic agents can be severe and include headache, back pain, diuresis, circulatory 
overload with angina, pulmonary edema and heart failure, and central nervous system effects 
such as obtundation, seizure, and cerebral hemorrhage. Because of these potentially serious 
side effects, they are not used as long-term agents. They are typically used in acute situations 
to temporarily reduce high IOP until more definitive treatments can be rendered (3).  
1.5.3 Laser treatment of glaucoma 
Indications for Laser treatment of glaucoma is failure and contraindication of 
medication therapy, meaning a failure of lowering IOP or continuous deterioration of the 
visual field. There are several laser procedures (3): 
I. Laser iridotomy 
Laser iridotomy is performed with a YAG laser cutting a small hole in the iris without 
surgical incision on the surface of the eye. The treatment is short and painless. Side 
effects are reversible loss of visual acuity. Anti-inflammatory eye drops are used 
several days after surgery (3). 
II. Laser trabeculoplasty (ALT/SLT) 
To avoid surgery, argon laser tabeculoplasty or selective argon trabeculoplasty (SLT) 
is used. It is used for primary open-angle glaucoma. Only 60% of patients are responsive to 
the therapy while the effects of the surgery last 3 years. SLT can be repeated (3). 
1.5.4 Surgical therapy of glaucoma 
The aim of surgical therapy is the decrease and stabilization IOP to maintain the 
existing visual acuity and visual field. Indications for surgery are high IOP despite medical or 
laser therapy or when the damage progresses despite conservative therapy. Methods of 
operative treatment are: trabeculotomy, deep sclerotomy and viscocanalostomy. The aim is to 
increase the outflow of aqueous humor (3). 
1.5.5 Combined therapy 
Nowadays there is a possibility of combined laser and medical treatment. A high 
number of patients require ongoing medical therapy after glaucoma surgery (3). 
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1.6 Treatment Guidelines from the European Glaucoma Society 
The aim of glaucoma therapy is to maintain the patient’s visual and quality of life, at 
sustainable costs. Careful evaluation hast to be applied to the cost of treatment in terms of 
inconvenience and side effects as well as social and individual financial implications. Quality 
of life is linked with visual function. Patients with early to moderate glaucomatous damage 
have good visual function and therefore only small reduction in quality of life. Quality of life 
is considerably reduced if both eyes are affected by visual function loss (15). 
For this reason it is important to have individualized treatment of glaucoma that aims 
at providing glaucoma management tailored to the individual needs of the patient. Severe 
functional loss or young patients with manifested disease have to be exposed to more 
aggressive treatment and close follow-up than little or no risk patients (15). 
1.6.1 Recommendations for Anti-Glaucoma Drug (AGD) prescriptions 
The European Glaucoma Society (EGS) recommends initiating treatment with 
monotherapy. A meta analysis of randomized controlled trials has shown that the highest 
reduction of IOP is obtained with prostaglandins followed by non-selective beta blockers, 
alpha adrenergic agonists, selective b-blockers and finally topical carbonic anhydrase 
inhibitors (38). 
If initial therapy is unsuccessful with no reach in target pressure or intolerance for the 
drug, another monotherapy should be tried before adding a second drug. This rule applies also 
to prostaglandin analogues (PGA) used as first choice. As there are non-responders to certain 
PGAs it is advised to switch to another PGA or another class of monotherapy. Laser therapy 
may also be therapeutical (15). 
If first choice monotherapy is tolerated but fails to provide a lowering of pressure to 
the target IOP addition of a second drug should be considered. The recommendation by the 
EGS is to combine agents with different modes of action, one affecting production of aqueous 
humour and another influencing outflow for example. Because polydrug regiments for 
treatment of glaucoma may lead to bad adherence to the drugs, reduced efficacy through 
wash-out medications and increased exposure to preservatives (39) fixed-dose combination 
therapy, when available, is advised (15).  
1.6.2 EGS on Prostaglandin Analogues 
Since PGAs have been developed in the 1990s, they have progressively replaced beta-
blockers as first-choice/first-line treatment. The reason for that is that they are simply the 
most effective IOP-lowering agents, lacking relevant systemic side effects and requiring just 
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once-daily administration (40). The primary mechanism of action of prostaglandins is to 
maximize uveoscleral outflow which reduces IOP by 25%-35%. The reduction of IOP starts 
2-4 h after the initial administration with its highest effect within 8-12 h (15). Also patients 
that are treated with PGAs have reduced short term IOP variability compared to patients 
treated with other classes of drugs (41). When combined with most other drug classes, PGAs 
exhibit additional IOP lowering. There are fewer than 10% non-responders to prostaglandin 
therapy (e.g. eyes with fewer reduction of IOP 10% or 15% from baseline) (42). Mild 
conjunctival hyperaemia is a common finding but usually decreases over time. 
 
1.6.3 EGS on Generic Medications 
By definition generic drugs are indistinguishable to brand name drugs in dosage, route 
of administration, strength, intended use and performance characteristics. For 
ophthalmological purposes this concept of “essential similarity” is problematic as it is hard to 
prove through clinical studies. With systemic drugs, bioequivalence studies from blood 
samples can be performed. Here, plasma concentrations within certain borders that equal the 
original drug can be determined. Such studies are impossible for topical eyedrops. There are 
no requires for clinical studies for generic approval in ophthalmology and 10% difference in 
concentration of the active principle between generic drugs and originals is considered 
acceptable. Whereas the active principle is assumed equal, there can be variations in 
adjuvants. The problem lies in the different adjuvants that may lead to alterations in viscosity, 
osmolarity and pH of the eye drops and therefore lead to tolerability and corneal penetration 
issues. Nevertheless there is a huge demand for generic glaucoma drugs as many of them are 
becoming of patent. For Latanoprost the generic share is 65% in Europe. The advice of the 
European Glaucoma Society is to monitor the patients’ IOP closely when switching from 
branded to generic drugs (15). 
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2. OBJECTIVES 
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The primary aim of this research is to find out the total number of anti-glaucoma drugs 
in Split-Dalmatia county from 2012-2016, especially with regards to consumption of original 
anti-glaucoma drugs against their generic counterparts and comparison between fixed 
(combined) and mono therapy. Also we want to show if the prescription of prostaglandin 
analogues has risen through the years. 
In addition, we want to prove that the guidelines of the European Glaucoma Society 
(EGS) are respected by showing that in Split-Dalmatia County the number of original anti-
glaucoma therapy, fixed-dose combinations and prostaglandin analogues are trending 
compared to other groups of medications.  
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3. PATIENTS AND METHODS 
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3.1   Methods and gathering of data 
For the completion of the study it was necessary to collect data about the number of 
consumed anti-glaucoma drugs (AGD) in the Split-Dalmatian County from 2012-2016 from 
glaucoma patients. The data about AGD was collected in pharmacies of the Split-Dalmatia 
County. The data is gathered from 36 pharmacies in the Split-Dalmatia County. 
The data gave following insight: 
1. The total number of anti-glaucoma drugs (AGD) in Split-Dalmatia County 
2. The number of sold AGD divided in groups in Split-Dalmatia County 
3.2 Statistical analysis 
The gathered data was inserted into Microsoft Office Excel for Windows. For 
statistical analysis the software Statistic 8.0 was used. In the processing of the data we used 
the Pearson correlation coefficient. The results were interpreted at a significance level of 
p<0.05.  
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The table beneath shows the total amount of original glaucoma drugs divided in their specific 
subgroups. The consumed amount of each drug group is shown through the years 2012-2016 
as well as the percentage to the total amount of original drugs (Tabel 1). 
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Table 1. Presentation of total amount of original anti-glaucoma drugs consumed in Split- 
Dalmatia County from the years 2012-2016 
 YEAR   ORIGINAL ANTIGLAUCOMA DRUGS 2012 2013 2014 2015 2016 TOTAL 
% of consumed drugs from 2012-2016 yr.         MONOCOMPONENT        ALPHA 2 AGONISTS        ALPHAGAN 9631 10437 10885 10943 12229 54125 7.2 BETA BLOCKERS        TIMALEN 0.25 % 1324 1311 1392 1271 1156 6454 0.85 TIMALEN 0.5 %  39202 36047 34196 33253 32347 175045 23.2 BETOPTIC 0.5 %  7575 7187 7331 7582 8338 38013 5.0 VISTAGAN 0.5 % 5174 5195 4586 3821 346 19122 2.5 LOCAL CAI        AZOPT  19196 18560 18466 16127 15900 88249 11.7 TRUSOPT  4061 3977 4434 4852 5517 22841 3.0 PROSTAGLANDINS AND PROSTAMIDE        XALATAN  18897 18499 19986 21258 21583 100223 13.3 LUMIGAN 0.01 %  0 0 30 478 1712 2220 0.29 LUMIGAN 0.03 %  3612 4202 3933 3385 2072 17204 2.3 TRAVATAN  6510 5947 5048 4358 3941 25804 3.4 SAFLUTAN 0 181 1316 1492 2241 5230 0.69 SUM OF MONOCOMPONENT DRUGS 115182 111543 111603 108820 107382 554530          FIXED DOSE COMBINATIONS        PROSTANGLANDINS AND PROSTAMIDE AND BETA BLOCKERS 
     
 
 XALACOM  3377 3940 4686 5606 6477 24086 3.2 DUOTRAV  867 916 909 971 858 4521 0.6 GANFORT  1755 2087 2231 2119 2072 10264 1.36 LOCAL CAI AND BETA BLOCKERS        AZARGA  2019 2560 3343 3802 4033 15757 2.1 COSOPT  23047 26519 28211 29872 33018 140667 18.6 ALPHA 2 AGONISTS AND BETA BLOCKERS 
       COMBIGAN  284 893 1404 1607 1322 5510 0.73 SUM OF FDC DRUGS 31349 36915 40784 43977 47780 200805  TOTAL SUM 146531 148458 152387 152797 155162 755335 100  
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The second table shows the total amount of generic glaucoma drugs also divided into their 
specific subgroups. The consumed amount of each drug group is shown through the years 
2012-2016 as well as the percentage to the total amount of generic drugs (Tabel 2).  
 
Table 2. Presentation of total amount of generic anti-glaucoma drugs consumed in Split- 
Dalmatia County from the years 2012-2016. 
 YEAR   GENERIC ANTIGLAUCOMA DRUGS 2012 2013 2014 2015 2016 TOTAL 
% of consumed drugs from 2012-2016 yr.         MONOCOMPONENT        ALPHA 2 AGONISTS        LUXFEN 0 0 181 316 408 905 3,1 BIMANOX 0 0 34 227 80 341 1,2 BETA BLOCKERS         TIMLATAN 0 0 59 342 431 832 2,9 LOCALCAI         DORSOL 0 91 361 649 115 1216 4,2 OFTIDOR 0 0 38 112 249 399 1,4 ULOM 0 0 2 3 21 26 0,1 PROSTAGLANDINS AND PROSTAMID         LATANOX 3311 4051 3908 4263 4768 20301 70,5 LATAPRES  0 0 107 358 405 870 3,0 SUM OF MONOCOMPONENT DRUGS 3311 4142 4690 6270 6477 24890 86,5          FIXED DOSE COMBINATIONS         LOCAL CAI AND BETA BLOCKERS         GLAUMAX 0 149 681 932 769 2531 8,8 OFTIDORIX 0 0 361 536 437 1334 4,6 ULOM PLUS 0 9 19 5 0 33 0,1 SUM OF FDC DRUGS 0 158 1061 1473 1206 3898 13,5           TOTAL SUM 3311 4300 5751 7743 7683 28788 100  
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Figure 2 shows the total amount of consumed anti-glaucoma medications through the years of 
2012-2016. We can see a rise of 13003 drugs in 5 years which can mean a rising awareness 
for glaucoma detection a treatment initiation. 
 
 
 
 
Figure 2. Presentation of the amount of consumed anti-glaucoma drugs in Split- Dalmatia 
County from 2012- 2016. The amount of drugs consumed is rising through years (r=0.987; 
p=0.002) 
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Figure 3 shows the consumption share of the individual drug groups through the year from 
2012-2016. We can see respect to the Guidelines of the European Glaucoma Society by 
increasing share of original fixed combinations. 
                
Figure 3.    Presentation of consumption share (%) of individual anti-glaucoma drug 
groups from 2012-2016. 
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 Figure 4 shows the consumption share in percent of the individual groups of original drugs 
from the total amount of original drugs from 2012
 
 
 
 
 
 
 
 
 
 
Figure 4.   Consumption share (%) of individual groups of the original anti
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Figure 5 shows the consumption share in percent of the individual groups of generic 
drugs from the total amount of generic drugs from 2012
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Figure 6 shows the rise of consumption of prostaglandin/ prostamide analogues through 
the years 2012-2016. The blue curve shows the original prostaglandins and the orange 
curve their generic counterparts.  
 
 
   Figure 6. Presentation of the amount of consumption of original and generic 
prostaglandin/ prostamide analogue drugs in Split- Dalmatia county from 2012- 2016. 
 
 
The amount of consumed original prostaglandin analogues has an increasing trend from 
2012-2016. (r=0.8692; P=0,007). 
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5. DISCUSSION 
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Right now, the World Health Organization (WHO) regards glaucoma as the third most 
common cause for blindness worldwide. It is responsible for 15% of all registered cases with 
an incidence of 2.4 million people per year. In people over the age of 50 glaucoma is the 
second most common cause of blindness (33). Estimates say that about 70 million people 
worldwide are affected by glaucomatous damage with only half of them being aware of the 
diagnosis. Even less percent of the affected receive adequate treatment. Minimum seven 
million people with glaucoma are blind in both eyes with the numbers increasing (3). 
The treatment of glaucoma is often complicated by individually differing responses 
and adherence rates to identical therapies, leading to variable outcomes (11). To make matters 
more elaborate, standard measurements of therapeutic response, such as IOP-lowering, are 
subject to relative imprecision and poor visit-to-visit repeatability (12).  
Lowering of the increased ocular pressure (IOP) is essential because IOP is the only 
factor that can be influenced (3). The initial therapy of glaucoma is medical therapy in form of 
drugs. Topical or local use in form of eye drops is the most common application form. The 
cost of IOP lowering medications can be a significant monthly strain on the budgets of 
patients and although patients may report that they are using daily medical therapy, data 
reveals just under 50% of persistence in annual use of therapy (34). Introducing generic 
glaucoma eye drops into the market has lowered costs for patients and lead to more adherence 
in some patient groups, albeit raising concerns for equivalence in efficacy and possible side 
effects (35).  
The ophthalmological community struggles with the concept of “essential similarity” 
of generic medications as it is hard to prove through clinical studies. The bioequivalence of 
systemic drugs can be studied from blood samples. Here plasma concentrations within certain 
borders that equal the original drug can be determined. Such studies are impossible for topical 
eyedrops. There are no requires for clinical studies for generic approval in ophthalmology and 
10% difference in concentration of the active principle between generic drugs and originals is 
considered acceptable. Whereas the active principle is assumed equal, there can be variations 
in adjuvants. The problem lies therein that different adjuvants may lead to alterations in 
viscosity, osmolarity and pH of the eye drops and therefore lead to tolerability and corneal 
penetration issues. Nevertheless there is a huge demand for generic glaucoma drugs as many 
of them are becoming off patent. For Latanoprost the generic share is 65% in Europe. In the 
year 2007 a study from the Indian Journal of Ophtalmology published that Xalatan (original 
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Latanoprost) reduced IOP by 37% on average while generic Latanoprost reduced IOP by only 
25% (36).  
 The advice of the European Glaucoma Society is to monitor the patients’ IOP closely 
when switching from branded to generic drugs (15). 
The following results will show the numbers of prescriptions of anti-glaucoma 
medication in the Split-Dalmatia County. From the results we will be able to see if there is a 
general trend in the counties medical community prescribing original drugs over their generic 
counterparts, if there are more prescriptions of fixed-dose combinations and also if the 
number of prescribed prostaglandin analogues has risen. 
In our study we showed that of the total amount of consumed anti-glaucoma drugs 
(n=784123), the highest amount takes consumption of original mono-component drugs 
(n=554530 or 71%) which makes it 2.8 times more than consumption of original fixed dose 
combination drugs, 23,7 times more than generic mono-component drugs and 71 times more 
than generic fixed dose combination drugs. The amount of original drugs spent (n=755335) in 
Split- Dalmatia County is 26 times higher compared to generic drugs (n=28788). Among 
original drugs, 73% are monocomponent drugs while 14% are fixed dose combination drugs. 
Consumption share of the original mono-component drugs shows a decreasing trend 
from 2012-2016 while consumption share of the original fixed dose combination drugs shows 
an increasing trend from 2012- 2016. Furthermore, consumption share of the generic mono-
component drugs shows an increasing trend from 2012.- 2016 and also consumption share of 
generic fixed dose combination drugs shows an increasing trend from 2012-2016. (r=0,253; 
p=0,681). 
Also we can see that the amount of consumed original prostaglandin analogues has an 
increasing trend from 2012-2016 (r=0.8692; P=0,007) and the amount of consumed generic 
prostaglandin analogues also has an increasing trend from 2012-2016 (r=0.9384; P=0,002). 
Conclusively we can say that the increasing trend in prescribing prostaglandin 
analogues, the increasing trend in prescribing fixed-dose combinations and  generally much 
higher sales numbers in original anti-glaucoma medications show the tendency in the Split-
Dalmatia counties’ ophthalmological community to follow the recommendations of the 
European Glaucoma Society(EGS). 
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6. CONCLUSIONS 
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1. There is a greater number of original anti-glaucoma medication prescriptions than 
generic ones. 
2. We can see an increasing number of fixed-dose combination therapy in Split-Dalmatia 
County from 2012-2016. 
3. The prescription of generic and original prostaglandin analogues in the Split-Dalmatia 
County is increasing constantly from 2012-2016. 
4. The rising trend of fixed-dose combinations, the high numbers of original brand drugs 
over generic ones and the increase of prostaglandin analogue sales show a tendency to 
follow guidelines by the Split-Dalmatia County with respect to the European 
Glaucoma Society (EGS). 
5. Recent development has shown that original anti-glaucoma Drugs are made without 
preservatives due to the susceptibility of the anterior eye segment to their toxic effects. 
Benzalkonium chloride (BAK) and Polyquad are the main conservans that are 
excluded because of their tendency to cause ocular surface disease (OSD). 
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Aim of the thesis: The primary aim of this research in medical anti-glaucoma therapy 
is to find out the total number of anti-glaucoma drugs in Split-Dalmatia county in the last 5 
years, especially with regards to consumption of original anti-glaucoma drugs against their 
generic counterparts and comparison between fixed (combined) and mono therapy. Also we 
want to show if the prescription of prostaglandin analogues has risen through the years. 
Patients and methods:  In this research we used data of the number of anti-glaucoma 
drugs used in Split- Dalmatia County between the years of 2012 and 2016 from glaucoma 
patients. The data is collected in pharmacies of the county. In this research the data gathered 
from the pharmacies have been retrospectively statistically and analytically analysed. The 
data was processed in Microsoft Excel and Microsoft Word programs. 
In the processing of the data we used the Pearson correlation coefficient. The results 
were interpreted at a significance level of p<0.05. The data was processed and shown with the 
help of Microsoft Excel and Microsoft Word programs.   
Results: In our study we showed that of the total amount of consumed anti-glaucoma 
drugs (n=784123), the highest amount takes consumption of original mono-component drugs 
(n=554530 or 71%) which makes it 23.7 times more than generic mono-component drugs. 
The amount of original drugs spent (n= 755335) in Split- Dalmatia county is 26 times higher 
compared to generic drugs (n=28788). Among original drugs, 73% are monocomponent drugs 
while 14% are fixed dose combination drugs. Consumption share of the original mono-
component drugs shows a decreasing trend from 2012- 2016 while consumption share of the 
original fixed dose combination drugs shows an increasing trend from 2012- 2016. Also we 
can see that the amount of consumed original prostaglandin analogues has an increasing trend 
from 2012-2016 (r=0.8692; P=0.007) and the amount of consumed generic prostaglandin 
analogues also has an increasing trend from 2012-2016 (r=0.9384; P=0.002). 
Conclusion: Conclusively we can say that the increasing trend in prescribing 
prostaglandin analogues, an increasing trend in prescribing fixed-dose combinations and 
generally much higher sales numbers in original anti-glaucoma medications show the 
tendency in the Split-Dalmatian counties’ ophthalmological community to follow the 
guidelines of the European Glaucoma Society. 
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9. SAŽETAK 
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Naslov: Usporedba generičkih i originalnih antiglukomskih ljekova u Splitsko-
dalmatinskoj županiji 
Cilj istraživanja: Primarni cilj ovog istraživanja je istražiti ukupan broj 
antiglaukomskih lijekova (AGL) u Splitsko-dalmatinskoj županiji u zadnjih 5 godina(2012-
2016), pogotovo usporedba konzumiranih originalnih antiglaukomskih lijekova sa 
genericima, zatim usporedbu između fiksne antiglaukomske terapije i monoterapije, te dali je 
porastao broj prodanih analoga prostaglandina/prostamida kroz 2012.-2016. god. 
Materials and methods: Za izradu ovog istraživanja bilo je nužno prikupiti podatke o 
broju potrošnji antiglaukomskih lijekova od 2012. do 2016. godine na području Splitsko-
dalmatinske županije.  
U obradi podataka smo koristili Pearson koeficijenta korelacije. Podaci su 
interpretirani na razini značajnosti p<0,05. Podatke, dobivene od ljekarna, smo obradili 
retrospektivno statistički i analitički. Rezultate smo prikazali tabelarno i grafički uz pomoč 
Microsoft Excel-a i Word-a. 
Results: U našem istraživanjem smo pokazali da od 2012.do 2016. god. Ukupan broj 
potrošenih ljekova je 784123, sa največim brojem potrošnje originalnih monokomponentnih 
lijekova (n=554530 ili 71%). Ima ih 23,7 puta više od generičkih monokomponentnih 
lijekova.  Ukupan broj originalnih lijekova (n=755335) u Splitsko-dalmatinskoj županiji je 26 
puta veči uspoređdeno sa generičkim lijekovima (n=28788). U skupini originalnih lijekova 
73% su monokomponentni lijekovi i 14% su fiksne kombinacije lijekova. Udio potrošnje 
originalnih monokomponentnih lijekova pokazuje padajuču tendeciju od 2012. do 2016. god. 
dok udio potrošnje originalnih fiksnih kombinacija pokazuje povečavanje od 2012. do 2016. 
god. Osim toga smo pokazali da je broj potrošenih originalnih analoga prostaglandina 
pokazuje povečavanje od 2012-2016 (r=0,8692;P=0,007) i broj potrošenih generičkih analoga 
prostaglandina pokazuje rast od 2012. do 2016. god. (r=0,9384;P=0,002). 
Zaključak: Na kraju možemo zaključiti da je veči broj potrošenih analoga 
prostaglandina, kombinirane fiksne terapije i generalno puno veči broj potrošenih originalnih 
antiglaukomskih lijekova pokazuje tendeciju Splitsko-dalmatinske oftalmološke zajednice 
sljediti preporuke i smijernice Europskog glaukomskog društva (EGS). 
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